Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery
Status:
Completed
Trial end date:
2014-01-16
Target enrollment:
Participant gender:
Summary
This phase II trial is studying the side effects of pazopanib hydrochloride and to see how
well it works in treating patients with metastatic melanoma that cannot be removed by
surgery. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth and by blocking blood flow to the tumor.